Parexel is a leading global biopharmaceutical services company, providing a broad range of expertise-based solutions and services throughout the lifecycle of product development for pharmaceutical, biotechnology, and medical device companies. Founded in the early 1980s, Parexel has grown into one of the world’s largest clinical research organizations (CROs), supporting clients with innovative approaches to clinical research, data management, regulatory affairs, and patient access solutions.

With a presence in over 100 countries, Parexel empowers clients to accelerate innovation, reduce development risk, and bring new therapies to market more quickly and efficiently. The company employs more than 21,000 professionals globally, leveraging extensive experience and deep therapeutic knowledge to address clients’ most complex clinical development challenges.

Parexel is recognized for its ability to guide clients through the complex regulatory landscape, having established a strong track record of successful interactions with global regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The company’s services are tailored to support all phases of clinical research, from early-stage development through post-marketing surveillance.

From its roots as a regulatory affairs consultancy aiding small research companies, Parexel has evolved to offer a comprehensive suite of solutions, including consulting, clinical trial management, biometrics, decentralized trial capabilities, real-world evidence, and technology-enabled innovations. Parexel’s ongoing commitment to advancing drug development and improving patient outcomes drives its investment in new methodologies and digital tools that enhance the efficiency and quality of clinical research.